BCR and gastric cancer: For further exploring the sensitive and non-sensitive mechanism of the combination therapy, we next performed functional enrichment analysis on the overrepresented proteins of XHSG and XHNSG [FC (XHNSG vs XHSG) >2 or <0.5], and observed that GC patients featured by TCR signaling, BCR signaling, and Fc epsilon RI signaling pathways showed non-sensitive to XELOX therapy but sensitive to XELOX combined with anti-HER2 targeted therapy (Supplementary Fig. 5e and Supplementary Data 8).